Skip to main content
Clinical Trials/JPRN-UMIN000020814
JPRN-UMIN000020814
Recruiting
未知

sefulness of FDG-PET/CT to predict the response after nivolumab in patients with previously treated advanced non-small cell lung cancer - FDG-PET/CT and prediction of nivolumab in lung cancer

Gunma0 sites30 target enrollmentFebruary 1, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Previously treated advanced non-small cell lung cancer
Sponsor
Gunma
Enrollment
30
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 1, 2016
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Gunma

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Pregnant woman 2\) Patients with obvious interstitial pneumonia or pulmonary fibrosis in the chest X\-ray. 3\) Patients with collagen vascular disease or autoimmune diseases 4\) Other cases attending physician it is determined unsuitable for registration of the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
sefulness of FDG-PET/CT to predict the response after anti-PD-1 antibody in patients with previously treated advanced non-small cell lung cancer: a multi-institutional studyPreviously treated advanced non-small cell lung cancer
JPRN-UMIN000031009Gunma University120
Unknown
Not Applicable
sefulness of FDG-PET/CT to predict the response after pembrolizumab in patients with PD-L1 positive advanced non-small cell lung canceradvanced non-small cell lung cancer
JPRN-UMIN000026730Gunma University Hospital50
Completed
Not Applicable
sefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot studyadvanced and recurrent non-small cell lung cancer
JPRN-UMIN000031095Kansai Medical University30
Active, not recruiting
Not Applicable
se of the PET-Scan examination in the evaluation of the treatment of patients diagnosed with Head and Neck CancerScamous Cell- Carcinoma of Head and NeckNeoplasmsPositron Emission Tomography Computed TomographyC04.557.470.200.400E01.370.350.350.800.700.500
RBR-9wwstdAC Camargo Cancer Center
Recruiting
Phase 1
FDG-PET/CT versus conventional CT for response monitoring in metastatic breast cancer: A pilot study for a randomized clinical trial (MONITOR-PILOT)Metastatic breast cancerTherapeutic area: Diseases [C] - Neoplasms [C04]Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
CTIS2023-506550-20-00Odense University Hospital30